IL111402A - Suspension of loteprednol etabonate for ear eye or nose treatment - Google Patents

Suspension of loteprednol etabonate for ear eye or nose treatment

Info

Publication number
IL111402A
IL111402A IL11140294A IL11140294A IL111402A IL 111402 A IL111402 A IL 111402A IL 11140294 A IL11140294 A IL 11140294A IL 11140294 A IL11140294 A IL 11140294A IL 111402 A IL111402 A IL 111402A
Authority
IL
Israel
Prior art keywords
suspension
loteprednol etabonate
nose treatment
ear eye
ear
Prior art date
Application number
IL11140294A
Other languages
English (en)
Other versions
IL111402A0 (en
Original Assignee
Pharmos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmos Corp filed Critical Pharmos Corp
Publication of IL111402A0 publication Critical patent/IL111402A0/xx
Publication of IL111402A publication Critical patent/IL111402A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79—Polymers of vinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Resins (AREA)
  • Steroid Compounds (AREA)
  • Electroluminescent Light Sources (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Adhesives Or Adhesive Processes (AREA)
IL11140294A 1993-10-25 1994-10-25 Suspension of loteprednol etabonate for ear eye or nose treatment IL111402A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/142,743 US5540930A (en) 1993-10-25 1993-10-25 Suspension of loteprednol etabonate for ear, eye, or nose treatment

Publications (2)

Publication Number Publication Date
IL111402A0 IL111402A0 (en) 1994-12-29
IL111402A true IL111402A (en) 2000-12-06

Family

ID=22501105

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11140294A IL111402A (en) 1993-10-25 1994-10-25 Suspension of loteprednol etabonate for ear eye or nose treatment

Country Status (17)

Country Link
US (2) US5540930A (de)
EP (1) EP0730443B1 (de)
JP (1) JP3570720B2 (de)
KR (1) KR100341497B1 (de)
AT (1) ATE217523T1 (de)
AU (1) AU697617B2 (de)
BR (1) BR9407958A (de)
CA (1) CA2174550C (de)
DE (1) DE69430635T2 (de)
DK (1) DK0730443T3 (de)
ES (1) ES2179851T3 (de)
HU (1) HU227316B1 (de)
IL (1) IL111402A (de)
NZ (1) NZ275749A (de)
PT (1) PT730443E (de)
SG (1) SG48768A1 (de)
WO (1) WO1995011669A1 (de)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849263A (en) * 1993-03-30 1998-12-15 Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
US5576311A (en) * 1994-11-30 1996-11-19 Pharmos Corporation Cyclodextrins as suspending agents for pharmaceutical suspensions
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
US5955097A (en) 1996-10-18 1999-09-21 Virotex Corporation Pharmaceutical preparation applicable to mucosal surfaces and body tissues
US5800832A (en) * 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
TW503113B (en) * 1997-01-16 2002-09-21 Senju Pharma Co Aqueous suspension for nasal administration
KR100508227B1 (ko) * 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 로테프레드놀에타보네이트수성현탁액
US20050048102A1 (en) * 1997-10-16 2005-03-03 Virotex Corporation Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
SE9704186D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
EP1050299A4 (de) * 1998-01-22 2007-05-02 Santen Pharmaceutical Co Ltd Augentropfen aus fluorometholonsuspension
US6103266A (en) * 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
WO2000012137A1 (en) * 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
CZ295595B6 (cs) * 1999-06-22 2005-08-17 Boehringer Ingelheim International Gmbh Stálý roztok xylometazolinu a oxymetazolinu
FR2796553B1 (fr) * 1999-07-22 2001-09-28 Warner Lambert Co Suspension de tixocortol pivalate, collutoire a base de celle-ci et conditionnement la contenant
DE60006262T2 (de) 1999-09-24 2004-05-13 Alcon, Inc. Topische suspensionsformulierungen enthaltend ciprofloxacin und dexamethason
AR026073A1 (es) 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica acuosa que contiene ciclesonida
KR20010089887A (ko) * 1999-10-20 2001-10-12 야스이 쇼사꾸 수성의약품 조성물
US20040097486A1 (en) * 1999-11-18 2004-05-20 Yanni John M. Use of an H1 antagonist and a safe steroid to treat eye conditions
CN1376066A (zh) * 1999-11-18 2002-10-23 爱尔康公司 H1拮抗剂和安全类固醇的治疗眼病的用途
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
WO2001087262A2 (en) * 2000-05-15 2001-11-22 Pharmacia Italia S.P.A. Stabilized steroidal suspension
CA2412575C (en) 2000-07-26 2009-12-29 Onkar N. Singh Improved process for manufacturing compositions containing ciprofloxacin and hydrocortisone
EP1337237B1 (de) * 2000-11-15 2009-03-11 Mohan A. Chandavarkar Pharmazeutische zusammensetzungen mit corticosteroiden und antiinfektiva
EP1341541A4 (de) * 2000-11-16 2004-11-17 Alcon Mfg Ltd Kombinationstherapie zur senkung und kontrolle des augeninnendrucks
US20030139382A1 (en) * 2001-09-21 2003-07-24 Alcon, Inc. Method of treating middle ear infections
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
US20090215735A1 (en) * 2002-02-25 2009-08-27 Alcon, Inc. Topical solution formulations containing a corticosteroid and a cyclodextrin
WO2004006957A1 (en) * 2002-07-15 2004-01-22 Alcon, Inc. Pharmaceutical compositions for otic use
PT1551417E (pt) * 2002-10-18 2008-10-31 Aqueous Pharma Ltd Formulação de lágrimas com três camadas
US20040151754A1 (en) * 2002-12-20 2004-08-05 Control Delivery Systems, Inc. Steroid suspensions for intraocular use
WO2004064828A1 (ja) 2003-01-21 2004-08-05 Senju Pharmaceutical Co., Ltd. ２−アミノ−３−(４−ブロモベンゾイル)フェニル酢酸含有水性液剤
US20050069590A1 (en) * 2003-09-30 2005-03-31 Buehler Gail K. Stable suspensions for medicinal dosages
US20050095205A1 (en) * 2003-10-31 2005-05-05 Ramesh Krishnamoorthy Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
US20050197303A1 (en) * 2003-10-31 2005-09-08 Bausch & Lomb Incorporated Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
US20090246281A1 (en) * 2003-11-03 2009-10-01 Norton Healthcare Ltd. Soft steroid compositions for use in dry powder inhalers
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
JP4820648B2 (ja) * 2003-12-02 2011-11-24 千寿製薬株式会社 ロテプレドノールエタボネート水性懸濁液剤
PE20050941A1 (es) 2003-12-16 2005-11-08 Nycomed Gmbh Suspensiones acuosas de ciclesonida para nebulizacion
EP1706095B1 (de) * 2004-01-20 2008-12-24 Allergan, Inc. Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon-acetonid und hyaluronsäure
WO2005072710A2 (en) * 2004-01-28 2005-08-11 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
US20050182039A1 (en) * 2004-02-13 2005-08-18 Bausch & Lomb Incorporated Use of Loteprednol etabonate for the treatment of dry eye
AU2005229006B9 (en) * 2004-03-25 2011-05-19 Bausch & Lomb Incorporated Use of loteprednol etabonate for the treatment of dry eye
US20050234018A1 (en) * 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
AU2005271700B2 (en) * 2004-07-12 2010-11-11 Allergan, Inc. Opthalmic compositions and methods for treating ophthalmic conditions
CA2580659C (en) * 2004-09-15 2013-02-26 Ivx Animal Health, Inc. Corticosteroid having low systemic absorption
WO2006043965A1 (en) * 2004-10-14 2006-04-27 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
SI1885336T1 (sl) * 2005-05-10 2009-08-31 Alcon Inc Suspenzijske formulacije, ki obsegajo aktivno sestavino, poloksamerni ali meroksapolni surfaktant in glikol, in njihova uporaba za pripravo zdravila za zdravljenje oftalmičnih motenj
AU2006244245B2 (en) * 2005-05-10 2010-11-18 Alcon, Inc. Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
CN101272807A (zh) * 2005-09-26 2008-09-24 皮埃蒙特医药品有限公司 使用非离子表面活性剂促进跨膜药物输送到中耳治疗和预防中耳炎的方法
EP1928439A4 (de) * 2005-09-26 2009-04-29 Piedmont Pharmaceuticals Llc Verfahren zur behandlung und prävention von otitis media mit chemischen penetrationsverstärkern zur erleichterung der transmembranösen arzneiabgabe in das mittelohr
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
MX339797B (es) 2005-10-18 2016-06-10 Allergan Inc Terapia ocular que usa derivados glucocorticoides que penetran selectivamente los tejidos del segmento posterior.
US20070093461A1 (en) * 2005-10-26 2007-04-26 Bausch & Lomb Incorporated Effect of Loteprednol etabonate on vascular dysfunction
WO2007058935A2 (en) * 2005-11-14 2007-05-24 Bausch & Lomb Incorporated Ophthalmic composition for dry eye therapy
US20070128251A1 (en) * 2005-12-07 2007-06-07 Piedmont Pharmaceuticals, Inc. Process for manufacturing chewable dosage forms for drug delivery and products thereof
US7955632B2 (en) 2005-12-07 2011-06-07 Bayer B.V. Process for manufacturing chewable dosage forms for drug delivery and products thereof
EP2522343A1 (de) 2006-03-28 2012-11-14 Javelin Pharmaceuticals, Inc. Formulierungen aus niedrigdosiertem Diclofenac und Beta-Cyclodextrin
MX2008012496A (es) * 2006-03-28 2009-01-07 Javelin Pharmaceuticals Inc Formulaciones de farmacos anti-inflamatorios no esteroidales de baja dosis y beta-ciclodextrina.
US20070238789A1 (en) * 2006-03-31 2007-10-11 Chin-Ming Chang Prednisolone acetate compositions
WO2008002118A1 (es) * 2006-06-27 2008-01-03 Arturo Jimenez Bayardo Una formulación oftálmica en suspensión de etabonato de loteprednol y clorhidrato de ciprofloxacina
ES2577390T3 (es) 2006-07-21 2016-07-14 Biodelivery Sciences International, Inc. Dispositivos de administración transmucosa con mayor captación
WO2008027341A2 (en) * 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
WO2008027340A2 (en) * 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
JP2010502713A (ja) * 2006-09-08 2010-01-28 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘液を通る輸送を増強するための組成物および方法
TWI415629B (zh) * 2006-10-26 2013-11-21 Otsuka Pharma Co Ltd 含有瑞巴匹特之水性醫藥懸浮物及其製造方法
WO2008057364A1 (en) * 2006-11-02 2008-05-15 Riolan Technologies, Inc. Method for treating blepharitis
WO2008057360A1 (en) * 2006-11-02 2008-05-15 Riolan Technologies, Inc. Methods of treating an ocular allergy with low dose dexamethasone
CN101721714B (zh) * 2009-12-18 2011-12-07 重庆莱美药业股份有限公司 实体瘤被动靶向性抗癌前药及其制备方法
US8889193B2 (en) 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
EP3045163A1 (de) * 2011-04-22 2016-07-20 Alcon Research, Ltd. Ophthalmische zusammensetzung mit einem viskositätsverstärkungssystem mit zwei unterschiedlichen viskositätsverstärkern
MX352959B (es) 2011-08-18 2017-12-15 Biodelivery Sciences Int Inc Dispositivos mucoadhesivos resistentes al abuso para el suministro de buprenorfina.
CA2851492A1 (en) 2011-09-22 2013-03-28 Bausch & Lomb Incorporated Ophthalmic gel compositions
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
US8962577B2 (en) 2012-03-16 2015-02-24 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
CA2867203C (en) 2012-03-16 2016-09-20 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
WO2013166408A1 (en) * 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
CN111700878A (zh) * 2012-05-03 2020-09-25 卡拉制药公司 显示提高的粘膜转移的药物纳米粒子
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
CA2872519C (en) 2012-05-04 2017-09-05 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
CN103565742A (zh) * 2012-07-25 2014-02-12 天津金耀集团有限公司 氟米龙滴眼液
CN103565740A (zh) * 2012-07-25 2014-02-12 天津金耀集团有限公司 依碳氯替泼诺混悬滴眼液
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9353123B2 (en) 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US20150164882A1 (en) 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20160279055A1 (en) 2013-07-22 2016-09-29 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
SMT202200179T1 (it) * 2014-11-07 2022-07-21 Santen Pharmaceutical Co Ltd Composizione acquosa oftalmica.
JP6846351B2 (ja) 2015-01-27 2021-03-24 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘膜表面における活性薬剤の増強された輸送のための低張ヒドロゲル製剤
CN106279324A (zh) * 2015-05-27 2017-01-04 天津金耀集团有限公司 依碳氯替泼诺一水合物及其晶型与制备方法
CN106279325A (zh) * 2015-05-27 2017-01-04 天津金耀集团有限公司 一种依碳氯替泼诺新晶型及其制备方法
CN106892953A (zh) * 2015-12-21 2017-06-27 天津金耀集团有限公司 依碳氯替泼诺一水合物及其晶型与制备方法
CN106892952A (zh) * 2015-12-21 2017-06-27 天津金耀集团有限公司 一种依碳氯替泼诺新晶型及其制备方法
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2018048750A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (de) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. Kristalline formen therapeutischer verbindungen und verwendungen davon
WO2020210805A1 (en) 2019-04-11 2020-10-15 The Johns Hopkins University Nanoparticles for drug delivery to brain
US12023344B2 (en) 2022-05-25 2024-07-02 Famygen Life Sciences, Inc. Topical otic, ophthalmic, and nasal corticosteroid formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2861920A (en) * 1954-05-04 1958-11-25 Upjohn Co Therapeutic suspensions of steroids containing pvp and/or pva
US4409205A (en) * 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4710495A (en) * 1980-07-10 1987-12-01 Otsuka Pharmaceutical Co., Ltd. Soft steroids having anti-inflammatory activity
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
JPS6041607A (ja) * 1983-08-12 1985-03-05 Otsuka Pharmaceut Co Ltd 軟膏基剤
JPS6143114A (ja) * 1984-08-03 1986-03-01 Takeda Chem Ind Ltd 虹彩・毛様体疾患治療用眼局所投与剤
US5192535A (en) * 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
US5149693A (en) * 1988-03-09 1992-09-22 Alcon Laboratories, Inc. Combination of tobramycin and fluorometholone for topical ophthalmic use
NL8801670A (nl) * 1988-07-01 1990-02-01 Walter Adrianus Josephus Johan Farmaceutisch preparaat.
CA2003198C (en) * 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5277901A (en) * 1990-01-05 1994-01-11 Allergan, Inc. Ophthalmic compositions and methods for preserving and using same

Also Published As

Publication number Publication date
ATE217523T1 (de) 2002-06-15
US5747061A (en) 1998-05-05
NZ275749A (en) 1998-02-26
HU227316B1 (en) 2011-03-28
DE69430635T2 (de) 2003-01-02
HUT74882A (en) 1997-02-28
EP0730443A4 (de) 1997-11-05
JPH09504294A (ja) 1997-04-28
CA2174550C (en) 2002-10-01
DK0730443T3 (da) 2002-09-09
PT730443E (pt) 2002-11-29
EP0730443A1 (de) 1996-09-11
KR100341497B1 (ko) 2002-12-05
SG48768A1 (en) 1998-05-18
CA2174550A1 (en) 1995-05-04
WO1995011669A1 (en) 1995-05-04
KR960705541A (ko) 1996-11-08
AU697617B2 (en) 1998-10-15
EP0730443B1 (de) 2002-05-15
HU9601081D0 (en) 1996-06-28
US5540930A (en) 1996-07-30
AU7983594A (en) 1995-05-22
DE69430635D1 (de) 2002-06-20
BR9407958A (pt) 1996-11-26
IL111402A0 (en) 1994-12-29
JP3570720B2 (ja) 2004-09-29
ES2179851T3 (es) 2003-02-01

Similar Documents

Publication Publication Date Title
IL111402A0 (en) Suspension of loteprednol etabonate for ear, eye or nose treatment
IL114193A0 (en) Ophthalmic pharmaceutical compositions
AU7655194A (en) Active principles and gas containing microparticles
IL106128A0 (en) Vitamin d derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
CA2342211A1 (en) Antibiotic compositions for treatment of the eye, ear and nose
CA2310222A1 (en) New composition of matter
AU5058493A (en) Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
WO2000018388A3 (en) Antibiotic compositions for treatment of the eye, ear and nose
ES488888A1 (es) Procedimiento de fabricacion de una suspension acuosa de alumina
IL113178A (en) 8alpha-3-hydroxyestra-1,3,5(11)tetraen-17-one( 9(11)-dehydro-8-isoestrone) its preparation and pharmaceutical composition containing it
MXPA02004617A (es) Lipoxin a4 y sus analagos para el tratamiento de ojo reseco.
TW223061B (en) 9-(3-cyanophenyl)-3,4,6,7,9,10-hexahydro-1,8-(2h,5h)-acridinedione and pharmaceutical compositions containing same
CA2284551A1 (en) New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
WO2000018387A3 (en) Antibiotic compositions for treatment of the eye, ear and nose
HK1038692A1 (zh) 治疗眼、耳、鼻病症的抗生素合成剂
IT1254627B (it) Formulazioni di steroidi
AU7812794A (en) Pharmaceutical compositions containing n-acetylcarnosine for the treatment of cataract
AU5494298A (en) Pharmaceutical compositions for the treatment of the eye
AU641411B2 (en) Nitrofurantoin crystals
AU6295094A (en) Compositions for the treatment of eye diseases
PL311356A1 (en) Fungicide in the form of concentrated aqueous suspension especially for use as a seed dressing agent

Legal Events

Date Code Title Description
FF Patent granted
NE Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967)
KB Patent renewed
FF Patent granted
KB Patent renewed
EXP Patent expired